SEP 17 2002 JC12 PATENT & TRADEMARK OFFICE

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional): P01492US1

Application Number: 09/321,916

Applicant: Zoghbi, et al.

Filing Date: 05/28/99

Group Art Unit: ~~1633~~ 1632

RECEIVED
SEP 19 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENT(S)

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AMZ	1.	Barkats, M. et al.; Adenovirus in the Brain: Recent Advances of Gene Therapy for Neurodegenerative Diseases; *Prog. In Neurobiol.* 55:333-341 (1998).
	2.	Barkats, M. et al.; Intrastriatal Grafts of Embryonic Mesencephalic Rat Neurons Genetically Modified Using an Adenovirus Encoding Human Cu/Zn Superoxide Dismutase; *Neuroscience* 78:703-713 (1997).
	3.	Beissinger, Martina and Buchner, Johannes; How Chaperones Fold Proteins; *Biol. Chem.* 379:245-259 (1998).
	4.	Bilang-Bleuel, A. et al.; Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease; *Proc. Natl. Acad. Sci. USA* 94: 8818-8823 (1997).
	5.	Blömer, U. et al.; Applications of gene therapy to the CNS; *Hum. Mol. Genet.* 5:1397-1404 (1996).
	6.	Bruening, W. et al.; Up-Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis; *J. Neurochem.* 72:693-699 (1999).
	7.	Bukau, Bernd and Horwich, Arthur L.; The Hsp70 and Hsp60 Chaperone Machines; *Cell* 92:351-366 (1998).
	8.	Caughey, B. et al.; Congo Red Inhibition of Scrapie Agent Replication; *J. Virol.* 67:6270-6272 (1993).
	9.	Caughey, Byron and Race, Richard E.; Potent Inhibition of Scrapie-Associated PrP Accumulation by Congo Red; *J. Neurochem.* 59:768-771 (1992).
	10.	Caughey, Byron and Raymond, Gregory J.; Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells; *J. of Virol.* 67:643-650 (1993).
	11.	Cha, J-H. J.; et al.; Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease; *Phil. Trans. R. Soc. Lond.* 354:981-989 (1999).
	12.	Chai, Y. et al.; Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation *in vitro*; *Hum. Mol. Gen.* 8:673-682 (1999).
	13.	Choi-Lundberg, D. L. et al.; Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy; *Science* 275:838-841 (1997).
	14.	Csermely, P. et al.; The 90-kDa Molecular Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive Review; *Pharmacol. Ther.* 79:129-168 (1998).
	15.	Cummings, C. J. et al.; Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1; *Nature Genet.* 19:148-154 (1998).
AMZ	16.	Cummings, Christopher J. and Huda Y. Zoghbi; Fourteen and counting: unraveling trinucleotide repeat diseases; *Hum. Mol. Gen.* 9:909-916 (2000).

EXAMINER	DATE CONSIDERED
Anne-Marie Falk	10/16/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PATENT & TRADEMARK OFFICE SEP 17 2002 JC12

RECEIVED
SEP 19 2002
TECH CENTER 1600/2900

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional)	Application Number
P01492US1	09/321,916
Applicant: Zoghbi, et al.	
Filing Date: 05/28/99	Group Art Unit ~~1633~~ 1632

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENT(S)

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AMA	17.	Cummings, C. J. et al.; Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in *SCA1* Mice; *Neuron* X:879-892 (1999).
	18.	Déglon, N.; Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C_2C_{12} Myoblasts; *Hum. Gene Ther.* 7:2135-2146 (1996).
	19.	Doran S. E. et al.; Gene Expression from Recombinant Viral Vectors in the Central Nervous System after Blood-Brain Barrier Disruption; *Neurosurgery* 36:965-970 (1995).
	20.	Emerich, D. F. et al.; Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease; *Nature* 386:395-399 (1997).
	21.	Floyd, Jennifer A. and Hamilton, Bruce A.; Intranuclear Inclusions and the Ubiquitin-Proteasome Pathway: Digestion of a Red Herring?; *Neuron* 24(4):765-766 (1999).
	22.	Giménez y Ribotta, M. et al.; Prevention of Motoneuron Death by Adenovirus-Mediated Neurotrophic Factors; *J. Neurosci. Res.* 48:281-285 (1997).
	23.	Graham, Frank L. and Prevec, Ludvik; Chapter 11- Manipulation of Adenovirus Vectors; *Methods in Molecular Biology, Vol 7: Gene Transfer and Expression Protocols*; E. J. Murray, Ed.; The Humana Press Inc.; p. 109-128 (1991).
	24.	Haase, G. et al.; Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors; *Nature Medicine* 3:429-436 (1997).
	25.	Hedera, P. et al.; Spastic paraplegia, ataxia, mental retardation (SPAR): a novel genetic disorder; (abstract).
	26.	Hendrick, Joseph P. and Hartl, Franz-Ulrich; Molecular Chaperone Functions of Heat-Shock Proteins; *Annu. Rev. Biochem.* 62:349-384 (1993).
	27.	Horellou, P. et al.; Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease; *NeuroReport* 6:49-53 (1994).
	28.	Kaytor, Michael D. and Warren, Stephen T.; Aberrant Protein Deposition and Neurological Disease; *J. Biol. Chem.* 274:37507-37510 (1999).
	29.	Kazemi-Esfarjani, Parsa and Benzer, Seymour; Genetic Suppression of Polyglutamine Toxicity in *Drosophila*; *Science* 287:1837-1840 (2000).
	30.	Kobayashi, Y. et al.; Chaperones Hsp70 and Hsp40 Suppress Aggregate Formation and Apoptosis in Cultured Neuronal Cells Expressing Truncated Androgen Receptor Protein with Expanded Polyglutamine Tract; *J. Biol. Chem.* 275:8772-8778 (2000).
AMA	31.	Kojima, H. et al.; Construction and Characterization of Adenoviral Vector Expressing Biologically Active Brain-Derived Neurotrophic Factor; *Biochem. Biophys. Res. Commun.* 212:712-717 (1995).

EXAMINER	DATE CONSIDERED
Anne-Marie Falk	10/16/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

OIPE JC12
SEP 17 2002
PATENT & TRADEMARK OFFICE

RECEIVED
SEP 19 2002
TECH CENTER 1600/2900

PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional)	Application Number
P01492US1	09/321,916
Applicant: Zoghbi, et al.	
Filing Date: 05/28/99	Group Art Unit: ~~1633~~ 1632

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENT(S)

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AMA	32.	Koshy, Benna T. and Zoghbi Huda Y.; The CAG/Polyglutamine Tract Diseases: Gene Products and Molecular Pathogenesis; *Brain Pathol.* 7:927-942 (1997).
	33.	Krobitsch, Sylvia and Lindquist, Susan; Aggregation of huntington in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins; *Proc. Natl. Acad. Sci. USA* 97:1589-1594.
	34.	Le Gal La Salle, G. et al.; An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain; *Science* 259:988-990 (1993).
	35.	Lin, X et al.; Expanding Our Understanding of Polyglutamine Diseases through Mouse Models; *Neuron* 24:499-502 (1999).
	36.	Lowe, J. et al.; Ubiquitin is a Common Factor in Intermediate Filament Inclusion Bodies of Diverse Type in Man, Including those of Parkinson's Disease, Pick's Disease, and Alzheimer's Disease, as well as Rosenthal Fibres in Cerebellar Astrocytomas, Cytoplasmic Bodies in Muscle, and Mallory Bodies in Alcoholic Liver Disease; *J. of Pathol.* 155:9-15 (1988).
	37.	MacDonald, Marcy E.; gadzooks!; *Nature Genetics* 23:10-11 (1999).
	38.	Marber, M. S. et al.; Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury; *J. Clin. Invest.* 95:1446-1456 (1995).
	39.	Mayer, Matthias P. and Bukau, Bernd; Hsp70 Chaperone Systems: Diversity of Cellular Functions and Mechanism of Action; *Biol. Chem.* 379:261-268 (1998).
	40.	Mayer, R. J.; The ubiquitin/26S proteasome system and neurological disease - a personal view. (opinion).
	41.	Neuwelt, Edward A.; Cellular and Molecular Neurosurgery II - Comments; *Neurosurgery* 40:812-813 (1997).
	42.	Orr, Harry T. and Zoghbi, Huda Y.; Reversing Neurodegeneration: A Promise Unfolds; *Cell* 101:1-4 (2000).
	43.	Price, D. L. et al.; Neurodegenerative Diseases and Model Systems; *Neurodegenerative Diseases*; LXI:725-738 (1996).
	44.	Priola, S. A. et al.; Porphyrin and Phthalocyanine Antiscrapie Compounds; *Science* 287:1503-1506.
	45.	Richardson, A. et al.; The ins and outs of a molecular chaperone machine; TIBS 23:138-143 (1998).
	46.	Sabaté, O. et al.; Adenovirus for Neurodegenerative Diseases: In Vivo Strategies and Ex Vivo Gene Therapy Using Human Neural Progenitors; *Clin. Neurosci.* 3:317-321 (1996).
AMA	47.	Sato, T. et al.; Transgenic mice harboring a full-length human DRPLA gene with highly expanded CAG repeats exhibit severe disease phenotype (abstract).

EXAMINER	DATE CONSIDERED
Anne-Marie Falk	10/16/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

SEP 17 2002 JC12
PATENT & TRADEMARK OFFICE

RECEIVED
SEP 19 2002
TECH CENTER 1600/2900

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional)	Application Number
P01492US1	09/321,916
Applicant: Zoghbi, et al.	
Filing Date: 05/28/99	Group Art Unit: ~~1632~~ 1632

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENT(S)

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AMD	48.	Smith, David, F.; Sequence Motifs Shared between Chaperone Components Participating in the Assembly of Progesterone Receptor Complexes; *Biol. Chem.* 379:283-288 (1998).
	49.	Supattapone; S. et al.; Elimination of prioms by branched polyamines and implications for therapeutics; *Proc. Natl. Acad. Sci. USA* 96:14529-14534 (1999).
	50.	Tagliavini, F. et al.; Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters; *Science* 276:1119-1122 (1997).
	51.	Tran, Phuong B. and Miller, Richard J.; Aggregates in neurodegenerative disease: crowds and power?; *Trends Neurosci.* 22(5):194-197 (1999).
	52.	Wagey, Ravenska T. E. and Krieger, Charles; Abnormalities of protein kinases in neurodegenerative diseases; *Prog. in Drug Res.* 51:135-183 (1998).
	53.	Warrick, J. M. et al.; Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in *Drosophila*; *Cell*; 93:939-949 (1998).
	54.	Wyttenbach, A. et al.; Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease; *Proc. Natl. Acad. Sci. USA* 97:2898-2903 (2000).
	55.	Xu, W. et al.; Regulation of Microphthalmia-Associated Transcription Factor MITF Protein Levels by Association with the Ubiquitin-Conjugating Enzyme hUBC9; *Exp. Cell. Res.* 255:135-143 (2000).
	56.	Yamamoto, A. et al.; Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease; *Cell*; 101:57-66 (2000).
	57.	Yenari, M. A. et al.; Gene Therapy with HSP72 Is Neuroprotective in Rat Models of Stroke and Epilepsy; *Ann. Neurol.* 44:584-591 (1998).
	58.	Zlokovic, Berislav V. and Apuzzo, Michael L. J.; Cellular and Molecular Neurosurgery: Pathways from Concept to Reality--Part I: Target Disorders and Concept Approaches to Gene Therapy of the Centraol Nervous System; *Neurosurgery 40:789-803 (1997).*
AMD	59.	Zoghbi, Huda Y. and Orr, Harry T.; Polyglutamine diseases: protein cleavage and aggregation; *Curr. Opin. In Neurobiol.* 9:566-570 (1999).

EXAMINER	DATE CONSIDERED
Anne-Marie Falk	10/16/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

SEP 17 2002 C12 PATENT & TRADEMARK OFFICE

RECEIVED

SEP 19 2002

TECH CENTER 1600/2900

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional) P-01492-US1	Application Number 09/321,916
Applicant: Zoghbi, et al	
Filing Date: 5/28/99	Group Art Unit 1632

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AMA	5 7 7 3 2 4 5	06/30/98	Wittrup, et al.	435	69.1	05/15/95
AMA	5 6 8 8 6 5 1	11/18/97	Solomon	435	7.1	12/16/94
AMA	5 6 4 6 2 4 9	07/08/97	Kaye, et al.	530	350	08/28/94

FOREIGN PATENT DOCUMENT(S)

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AMA		STENOIEN, D.L., et al, "Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1 and are suppressed by the HDJ-2 chaperone" HUMAN MOLECULAR GENETICS, 1999, Vol. 8, No. 5, pp 2-11
AMA		CHAI, Y., et al, "Evidence for Proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation *in vitro*" HUMAN MOLECULAR GENETICS, 1999, Vol. 8, No. 4 pp 673-682
		MARK HOCHSTRASSER, "Ubiquitin-Dependent Protein Degradation" ANNU. REV. GENET. 1996, 30:405-39
		COUX, O., et al, "Structure and Functions of the 20S and 26S Proteasomes" ANNU. REV. BIOCHEM, 1996, 65:801-47
		HERSHKO, A., et al, "The Ubiquitin System for Protein Degradation" ANNU. REV. BIOCHEM, 1992, 61:761-807
		FRANK R. SHARP, M.D., "Stress Genes Protect Brain" ANNUALS OF NEUROLOGY, 10/1998, pp 581-3
		CYR, D.M., et al, "Regulation of Hsp70 Function by a Eukaryotic DnaJ Homolog" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 267, No. 29, October 15, 1992, pp. 20927-20931
		DOUGLAS M. CYR, "Cooperation of the molecular chaperone Ydj1 with specific Hsp70 homologs to suppress protein aggregation" FEBS LETTERS 359 (1995) pp 129-132
		WELCH, W.J., et al, "Chaperoning brain diseases" NATURE, Vol. 392, March 1998, pp 23-24
AMA		F. ULRICH HARTL, "Molecular chaperones in cellular protein folding" NATURE, Vol. 381, 13 June 1996, pp 571-580

 Anne-Marie Falk 10/16/03

SEP 17 2002 G12 PATENT & TRADEMARK OFFICE

		Sheet 2 of 2
Amj		TANG, Y., et al, "A Role for *HDJ-2/HSDJ in Correcting Subnuclear Trafficking, Transactivation, and Transrepression* Defects of a Glucocorticoid Receptor Zinc Finger Mutant" MOLECULAR BIOLOGY OF THE CELL., Vol. 8, May 1997, pp 795-809
		LU, Z., et al, "The conserved Carboxyl Terminus and Zinc Finger-like Domain of the Co-chaperone Ydj1 Assist Hsp70 in Protein Folding" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 10, March 6, 1998, pp 5970-5978
		BUKAU, B., et al, "The Hsp70 and Hsp60 Chaperone Machines" CELL, Vol. 92, pp 351-366, February 6, 1998
		GLOVER, J.R., et al, "Hsp104, Hsp70, and Hsp40: A Novel Chaperone System that Rescues Previously Aggregated Proteins" CELL, Vol. 94, pp 73-82, July 10, 1998
		BUSH, K.T., et al, "Proteasome Inhibition Leads to a Heat-shock Response, Induction of Endoplasmic Reticulum Chaperones, and Thermotolerance" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 14, April 4, 1997, pp 9086-9092
		HENRY L. PAULSON, "Human Genetics '99: Trinuletide Repeats Protein Fate in Neurodegenerative Proteinopathies: Polyglutamine Diseases Join the (Mis)Fold" AM. J. HUM. GENET., 1999, 64:339-345
		ALVES-RODRIGUES, A., et al, "Ubiquitin, cellular inclusions and their roll in neurodegeneration" TRENDS NEUROSCI (1998) 21, 516-520
		BURRIGHT, E.N., et al, "*SCA1 Transgenic Mice: A Model for Neurodegeneration Caused by an Expanded CAG* Trinucleotide Repeat" CELL, Vol. 82, pp 937-948, September 22, 1995
		AARON CIECHANOVER, "The ubiquitin-proteasome pathway: on protein death and cell life" THE EMBO JOURNAL, Vol. 17, No. 24, pp 7151-7160, 1998
		PAULSON, H.L., et al, "Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3" NEURON, Vol. 19, pp 333-344, August, 1997
		SKINNER, P.J., et al, "Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures" LETTERS TO NATURE, #21, #1834 pp 971-974
		STENOIEN, D.L., et al, "Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone" HUMAN MOLECULAR GENETICS, 1999, Vol. 8, No. 5, pp 731-741
		DiFIGLIA, M., et al, "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain" SCIENCE, Vol. 277, 26 September 1997, pp 1990-1993
		CHERNOFF, Y.O., et al, "Role of the Chaperone Protein Hsp104 in Propagation of the Yeast Prion-Like Factor [psi+]" SCIENCE, Vol. 268, 12 May 1995, pp 880-883
		MARBER, M.S., et al, "*Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases* the Resistance of the Heart to Ischemic Injury" J. CLIN. INVEST., Vol. 95, April 1995, pp 1446-1456
		SATO, K., et al, "HSP70 is essential to the neuroprotective effect of heat-shock" BRAIN RESEARCH 740 (1996) 117-123
		CHEETHAM, M.E., et al, "Human homologues of the bacterial heat-shock protein DnaJ are preferentially expressed in neurons" BIOCHEM. J., (1992) 284, 469-476
		DebBURMAN, S.K., et al, "Chaperone-supervised conversion of prion protein to its protease-resistant form" PROC. NATL. ACAD. SCI. USA, Vol. 94, pp 13938-13943, December 1997
		ZHOU, M., et al, "Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates *hsp72* Gene Transcription in HepG2 Cells" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 40, October 4, 1996, pp 24769-24775
		WARRICK, J., et al., "Suppression of polyglutamine-mediated neurodegeneration in *Drosophilia* by the molecular chaperone HSP70" Nature Genetics 2, Vol. 23 (1999)
↓		Bruening, W., et al., "Up-Regulation of Protein Chapeones Preserves Viability of Cells Expressing Toxic Cu/Zn-Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis", J. Neurochem. Vol. 72, No. 2, 1999
Amj		Chai, Y., et al., "Analysis of the Role of Heat Shock Protein (HSP) Molecular Chaperones in Polyglutamine Disease", J. Neurosci. 19(23):10338-10347 (1999)

EXAMINER	DATE CONSIDERED
Anne-Marie Falk	10/16/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

RECEIVED
SEP 19 2002
TECH CENTER 1600/2900